Imaging Biomarkers for Cystic Fibrosis
(BEGINNING Trial)
Trial Summary
The trial does not specify if you need to stop taking your current medications, but you must not have changed your chronic maintenance therapies in the 28 days before joining. If you are on ivacaftor therapy with certain mutations, you cannot participate.
Research shows that using Xenon Xe-129 in MRI scans can effectively detect early lung disease in cystic fibrosis patients and monitor their response to treatment. This imaging technique is sensitive in identifying ventilation issues and has shown significant improvements in lung function measurements after treatment.
12345Research indicates that hyperpolarized 129Xe MRI is being studied for its safety and tolerability in children, including those with cystic fibrosis, but detailed safety assessments are still ongoing.
12678The treatment 129Xe is unique for cystic fibrosis because it uses hyperpolarized xenon gas in MRI scans to provide detailed images of lung ventilation, allowing for early detection and monitoring of lung disease progression, which is more sensitive than traditional methods.
12459Eligibility Criteria
This trial is for children aged 6-8 with Cystic Fibrosis, who have high sweat chloride levels and two specific CFTR gene mutations. They must be able to undergo MRI scans, be clinically stable without recent respiratory infections or changes in maintenance therapies. Kids on ivacaftor therapy or with certain mutations can't join.Inclusion Criteria
Exclusion Criteria
Trial Timeline
Screening
Participants are screened for eligibility to participate in the trial
Pre Trikafta Treatment
Participants undergo 129Xe MRI to establish baseline measurements before starting triple-combination therapy
Post Trikafta Treatment
Participants receive triple-combination therapy and undergo 129Xe MRI to assess treatment effects
Follow-up
Participants are monitored for changes in ventilation defect percentage, pancreas volume, and other MRI measures
Participant Groups
129Xe is already approved in United States for the following indications:
- Evaluation of lung ventilation in adults and pediatric patients aged 12 years and older